RSS

Lenvima

The European Commission (EC) has granted a marketing authorisation for the oral receptor tyrosine kinase (RTK) inhibitor, LENVIMA (lenvatinib mesylate), as first-line treatment for adults with advanced or unresectable hepatocellular carcinoma (HCC). more

News

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. more

News